Sean M. Boyle, Ph.D.
Affiliations: | Genetics, Genomics and Bioinformatics | University of California, Riverside, Riverside, CA, United States |
Google:
"Sean Boyle"Mean distance: 18.05 (cluster 11) | S | N | B | C | P |
Parents
Sign in to add mentor| Anandasankar Ray | grad student | 2012 | UC Riverside | |
| (Computational Analysis of Receptor-Odor Interactions and Prediction of Behavior-Modifying Chemical Space.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Abbott C, Bedi N, Zhang SV, et al. (2020) Exome scale liquid biopsy characterization of putative neoantigens and genomic biomarkers pre- and post anti-PD-1 therapy in squamous cell carcinoma of the head and neck. Journal of Clinical Oncology. 38: 6557-6557 |
| Abbott CW, Bedi N, Zhang SV, et al. (2020) Abstract B18: Exome scale liquid biopsy monitoring of putative neoantigens and genomic biomarkers in patients on anti-PD-1 therapy in squamous cell carcinoma of the head and neck Cancer Immunology Research. 8 |
| Pyke RM, Abbott C, Mellacheruvu D, et al. (2020) Abstract 6678: Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance mechanism to anti-PD-1 therapy Cancer Research. 80: 6678-6678 |
| Abbott CW, Levy E, Pyke RM, et al. (2020) Abstract 4278: A composite neoantigen score is more strongly associated with therapeutic response than tumor mutational burden in a cohort of late-stage anti-PD-1-treated melanoma patients Clinical Trials. 80: 4278-4278 |
| Zhang SV, Tan M, Northcott JM, et al. (2020) Abstract 1989: Enhanced whole exome profiling of tumor circulating cell-free DNA enables sensitive assessment of tumor mutations Clinical Trials. 80: 1989-1989 |
| Power RP, Bartha G, Harris J, et al. (2020) Abstract 1334: A diagnostic platform for precision cancer therapy enabling composite biomarkers by combining tumor and immune features from an enhanced exome and transcriptome Cancer Research. 80: 1334-1334 |
| Mellacheruvu D, Phillips N, Bartha G, et al. (2019) Abstract 4536: Applying immunopeptidomics and machine learning to improve neoantigen prediction for therapeutic and diagnostic use Cancer Research. 79: 4536-4536 |
| Zhang SV, Abbott C, Li R, et al. (2019) Abstract 4695: Development and validation of an accurate exome-scale cfDNA detection platform Cancer Research. 79: 4695-4695 |
| Power R, Bartha G, Harris J, et al. (2019) Abstract A051: A comprehensive, highly accurate genomics platform for precision immunotherapy: Simultaneously characterize tumors and the TME from a single FFPE sample Molecular Cancer Therapeutics. 18 |
| Wang J, Boyle SM, Lee C, et al. (2018) Abstract 5710: Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment Cancer Research. 78: 5710-5710 |